Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX)
DAS (low or remission) · patients with rheumatoid arthritis in adults
Certolizumab pegol 200 mg sc (with or without MTX) leads to higher proportion of patients achieving DAS < 2.6 (remission) compared with placebo (with or without MTX) (high certainty).
1 finding from 1 review
- Certolizumab pegol (CDP870) for rheumatoid arthritis in adults 2017 · Cochrane Headline outcomes onlyRR 2.94 [1.64, 5.28]6 studies · 2420 participantsHigh